Compare CDP & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | ABCL |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 1996 | 2020 |
| Metric | CDP | ABCL |
|---|---|---|
| Price | $35.37 | $10.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $34.57 | $8.40 |
| AVG Volume (30 Days) | 678.2K | ★ 6.6M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | 8.94 | ★ 10.91 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $763,923,000.00 | $75,128,000.00 |
| Revenue This Year | $1.18 | N/A |
| Revenue Next Year | $3.71 | $21.85 |
| P/E Ratio | $47.47 | ★ N/A |
| Revenue Growth | 1.41 | ★ 160.56 |
| 52 Week Low | $27.06 | $2.75 |
| 52 Week High | $38.90 | $12.58 |
| Indicator | CDP | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 50.98 |
| Support Level | $33.21 | $10.44 |
| Resistance Level | $37.97 | $12.58 |
| Average True Range (ATR) | 0.83 | 0.65 |
| MACD | -0.18 | -0.29 |
| Stochastic Oscillator | 44.13 | 0.70 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. The company has two reportable segments: Defense/IT Portfolio; and Other. Defense/IT Portfolio includes sub-segments such as: Fort George G. Meade and the Baltimore/Washington Corridor (Fort Meade/BW Corridor); Redstone Arsenal in Huntsville, Alabama; Northern Virginia Defense/IT Locations (NoVA Defense/IT); Lackland Air Force Base in San Antonio, Texas; locations serving the U.S. Navy (Navy Support); and data center shells in Northern Virginia.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.